Adverse Outcomes Seen With MS Disease-Modifying Drugs in Pregnancy
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 2, 2025 -- Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes, including small for gestational age, according to a study published in the January issue of The Lancet Regional Health: Europe.
Nadine Bast, from Ruhr University Bochum in Germany, and colleagues conducted a prospective cohort study to examine pregnancy and neonatal outcomes in patients with MS. A total of 2,885 DMT-exposed and 837 DMT-unexposed pregnancies were compared.
The researchers found that exposure to DMTs was not associated with spontaneous abortions, preterm birth, or major congenital anomalies. Severe infections were rare but occurred more often in those exposed to fumarates (2.8 percent versus 1.0 percent in unexposed). Associations were seen for second-trimester and third-trimester natalizumab exposure and anti-CD20 exposure with systemic antibiotic use (odds ratios, 2.47, 1.75, and 2.16, respectively). Significant reductions in birth weight were seen in the sphingosine-1-phosphate group and the third-trimester natalizumab subgroup (β = −132 and −74 g, respectively). The sphingosine-1-phospate and anti-CD20 groups often had small-for-gestational-age neonates (odds ratios, 1.65 and 1.54, respectively); in the entire cohort, the rate exceeded the general German population rate (18.8 versus 10 percent).
"Our findings are critical to improve future pregnancy recommendations in women with MS seeking pregnancy by combining established and emerging evidence and increasing the number of reported pregnancies," the authors write.
The study was funded by pharmaceutical companies; several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
WEDNESDAY, April 9, 2025 -- Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous...
Higher Fish Intake Linked to Reduced Risk for MS Disability Worsening
FRIDAY, Feb. 28, 2025 -- Higher fish consumption is associated with slower disability progression in multiple sclerosis (MS), according to a study published online Feb. 25 in the...
Early Childhood Sun Exposure Linked to Lower Risk for Pediatric MS Relapse
WEDNESDAY, Feb. 12, 2025 -- Greater prenatal and early childhood sun exposure is associated with a lower risk for relapse among children with multiple sclerosis (MS), according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.